[
  {
    "ts": null,
    "headline": "Health Canada RSV Approval Adds New Angle To Merck Valuation Story",
    "summary": "Merck (NYSE:MRK) has received Health Canada approval for ENFLONSIA (clesrovimab), a monoclonal antibody for RSV prevention in newborns and infants. The product is indicated for the prevention of lower respiratory tract disease caused by RSV in this high risk population. The approval is supported by pivotal clinical trial data and extends Merck's infectious disease portfolio in Canada. For investors watching Merck at a share price of $121.93, this Health Canada decision adds a fresh...",
    "url": "https://finnhub.io/api/news?id=6d4c9512c2f29fa80eb7b1b4eb79a2eae13fae5feb21702597d2264d6edb744a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770484093,
      "headline": "Health Canada RSV Approval Adds New Angle To Merck Valuation Story",
      "id": 138386598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) has received Health Canada approval for ENFLONSIA (clesrovimab), a monoclonal antibody for RSV prevention in newborns and infants. The product is indicated for the prevention of lower respiratory tract disease caused by RSV in this high risk population. The approval is supported by pivotal clinical trial data and extends Merck's infectious disease portfolio in Canada. For investors watching Merck at a share price of $121.93, this Health Canada decision adds a fresh...",
      "url": "https://finnhub.io/api/news?id=6d4c9512c2f29fa80eb7b1b4eb79a2eae13fae5feb21702597d2264d6edb744a"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Merck & Co., Inc. on R. Dennis’s Substack’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc.’s share was trading at $106.90 as of January 28th. MRK’s trailing and forward P/E were 14.28 and 17.27 respectively according to Yahoo Finance. Merck & […]",
    "url": "https://finnhub.io/api/news?id=05859b30fe5737b86f4325c6e7ce2634a9e77ce0c540700aa98b9a7c7a2367eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770483039,
      "headline": "Merck & Co., Inc. (MRK): A Bull Case Theory",
      "id": 138386599,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Merck & Co., Inc. on R. Dennis’s Substack’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc.’s share was trading at $106.90 as of January 28th. MRK’s trailing and forward P/E were 14.28 and 17.27 respectively according to Yahoo Finance. Merck & […]",
      "url": "https://finnhub.io/api/news?id=05859b30fe5737b86f4325c6e7ce2634a9e77ce0c540700aa98b9a7c7a2367eb"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
    "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
    "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770453000,
      "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
      "id": 138384854,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154390775/image_2154390775.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
      "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d"
    }
  },
  {
    "ts": null,
    "headline": "5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (February 2026)",
    "summary": "Read the latest article in our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms.",
    "url": "https://finnhub.io/api/news?id=30c5616273b90ece4a037f60c3885635a35299c037515bbf85fea9969e1a0198",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770452400,
      "headline": "5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (February 2026)",
      "id": 138384798,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1249993252/image_1249993252.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Read the latest article in our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms.",
      "url": "https://finnhub.io/api/news?id=30c5616273b90ece4a037f60c3885635a35299c037515bbf85fea9969e1a0198"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says Stocks Like Johnson & Johnson “Simply Refuse to Quit”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer commented on. Cramer showed an optimistic sentiment toward the stock, as he commented: Lilly’s not alone. The irrepressible Johnson & Johnson, along with the effervescent Merck and Amgen, they simply refuse to quit. Why not? Even after the runs they’ve had this year alone, […]",
    "url": "https://finnhub.io/api/news?id=8a132567ee36620bfa4c1552aeef99b5fd0b08adab66ab869ce82953710c7f8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770443802,
      "headline": "Jim Cramer Says Stocks Like Johnson & Johnson “Simply Refuse to Quit”",
      "id": 138383220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer commented on. Cramer showed an optimistic sentiment toward the stock, as he commented: Lilly’s not alone. The irrepressible Johnson & Johnson, along with the effervescent Merck and Amgen, they simply refuse to quit. Why not? Even after the runs they’ve had this year alone, […]",
      "url": "https://finnhub.io/api/news?id=8a132567ee36620bfa4c1552aeef99b5fd0b08adab66ab869ce82953710c7f8b"
    }
  }
]